{
    "xml": "<topic id=\"PHP3827\" outputclass=\"drug\" rev=\"1.11\" type=\"drug\" namespace=\"/drugs/nevirapine\" basename=\"nevirapine\" title=\"NEVIRAPINE\">\n<title>NEVIRAPINE</title>\n<body>\r\n<p outputclass=\"interactionsLinks\"> List of individual interactants: <xref format=\"dita\" href=\"#bnf_int_843\" namespace=\"/interactions/list-of-drug-interactions/antivirals/nevirapine\">Nevirapine</xref>\n</p>\n<data name=\"vtmid\">108704001</data>\n<data name=\"classifications\">\n<data name=\"classification\">\n<data name=\"drugClassification\">\n<xref format=\"dita\" scope=\"local\" type=\"drugClassification\" href=\"#_645223670\" title=\"Non-nucleoside reverse transcriptase inhibitors\">Non-nucleoside reverse transcriptase inhibitors</xref>\n</data>\n</data>\n</data>\n<data name=\"primaryDomainOfEffect\">\n<data name=\"domainOfEffect\">  </data>\n</data>\r\n</body>\n<topic id=\"PHP54535\" outputclass=\"indicationsAndDose\" rev=\"1.66\" parent=\"/drugs/nevirapine\">\n<title>Indications and dose</title>\n<body>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">HIV infection in combination with other antiretroviral drugs (initial dose)</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By mouth using immediate-release medicines</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>Initially 200&#8239;mg once daily for first 14 days, initial dose titration using &#8216;immediate-release&#8217; preparation should not exceed 28 days; if rash occurs and is not resolved within 28 days, alternative treatment should be sought. If treatment interrupted for more than 7 days, restart using the lower dose of the &#8216;immediate-release&#8217; preparation for the first 14 days as for new treatment.</p>\n</li>\n</ul>\n</section>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">HIV infection in combination with other antiretroviral drugs (maintenance dose following initial dose titration if no rash present)</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By mouth using immediate-release medicines</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>200&#8239;mg twice daily.</p>\n</li>\n</ul>\n<p outputclass=\"routesOfAdministration\">By mouth using modified-release medicines</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>400&#8239;mg once daily.</p>\n</li>\n</ul>\n</section>\n</body>\n</topic>\n<topic id=\"PHP54717\" outputclass=\"contraindications\" rev=\"1.20\" parent=\"/drugs/nevirapine\">\n<title>Contra-indications</title>\n<body>\r\n<section outputclass=\"contraindications\">\r\n<p>\r\n<ph outputclass=\"contraindication\">\r\n<xref format=\"dita\" href=\"#PHP78608\" type=\"bookmark\" namespace=\"/treatment-summaries/acute-porphyrias\">Acute porphyrias</xref>\r\n</ph>; <ph outputclass=\"contraindication\">post-exposure prophylaxis</ph>\r\n</p>\r\n </section>\r\n\r\n\r\n\r\n\r\n\r\n\r\n</body>\n</topic>\n<topic id=\"PHP54779\" outputclass=\"cautions\" rev=\"1.30\" parent=\"/drugs/nevirapine\">\n<title>Cautions</title>\n<body>\n<section outputclass=\"cautions\">\n<p>\n<ph outputclass=\"caution\">Females (at greater risk of hepatic side effects)</ph>; <ph outputclass=\"caution\">high CD4 cell count (at greater risk of hepatic side effects)</ph>\n</p>\n</section>\n<section outputclass=\"importantAdvice\">\n<title>Cautions, further information</title>\n<sectiondiv>\n<p outputclass=\"title\">Hepatic effects</p>\n<p>Patients with chronic hepatitis B or C, high CD4 cell count, and women are at increased risk of hepatic side effects&#8212;if plasma HIV-1 RNA detectable, manufacturer advises avoid in women with CD4 cell count greater than 250&#8239;cells/mm<sup>3</sup> or in men with CD4 cell count greater than 400&#8239;cells/mm<sup>3</sup> unless potential benefit outweighs risk.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP54521\" outputclass=\"interactions\" rev=\"1.7\" parent=\"/drugs/nevirapine\">\n<title>Interactions</title>\n<body>\n<section outputclass=\"general\">\n<sectiondiv>\n<p>Appendix 1 (nevirapine).</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP68214\" outputclass=\"sideEffects\" rev=\"1.25\" parent=\"/drugs/nevirapine\">\n<title>Side-effects</title>\n<body>\r\n<section outputclass=\"generalSideEffects\">\r\n<sectiondiv outputclass=\"frequencies\">\r\n<sectiondiv outputclass=\"commonOrVeryCommon\">\r\n<p outputclass=\"title\">Common or very common</p>\r\n<p outputclass=\"sideEffects\">\r\n<ph outputclass=\"sideEffect\">Abdominal pain</ph>; <ph outputclass=\"sideEffect\">diarrhoea</ph>; <ph outputclass=\"sideEffect\">fatigue</ph>; <ph outputclass=\"sideEffect\">fever</ph>; <ph outputclass=\"sideEffect\">granulocytopenia</ph>; <ph outputclass=\"sideEffect\">headache</ph>; <ph outputclass=\"sideEffect\">hepatitis</ph>; <ph outputclass=\"sideEffect\">hypersensitivity reactions (may involve hepatic reactions and rash)</ph>; <ph outputclass=\"sideEffect\">nausea</ph>; <ph outputclass=\"sideEffect\">rash</ph>; <ph outputclass=\"sideEffect\">Stevens-Johnson syndrome</ph>; <ph outputclass=\"sideEffect\">toxic epidermal necrolysis</ph>; <ph outputclass=\"sideEffect\">vomiting</ph>\r\n</p>\n</sectiondiv>\r\n<sectiondiv outputclass=\"uncommon\">\r\n<p outputclass=\"title\">Uncommon</p>\r\n<p outputclass=\"sideEffects\">\r\n<ph outputclass=\"sideEffect\">Anaemia</ph>; <ph outputclass=\"sideEffect\">arthralgia</ph>; <ph outputclass=\"sideEffect\">myalgia</ph>\r\n</p>\n</sectiondiv>\r\n\r\n\r\n<sectiondiv outputclass=\"notKnown\">\r\n<p outputclass=\"title\">Frequency not known</p>\r\n<p outputclass=\"sideEffects\">\r\n<ph outputclass=\"sideEffect\">Osteonecrosis</ph>\r\n</p>\n</sectiondiv>\n</sectiondiv>\n</section>\r\n\r\n<section outputclass=\"sideEffectsAdvice\">\r\n<title>Side-effects, further information</title>\r\n<sectiondiv>\r\n<p outputclass=\"title\">Hepatic effects</p>\r\n<p>Potentially life-threatening hepatotoxicity including fatal fulminant hepatitis reported usually in first 6 weeks; discontinue permanently if abnormalities in liver function tests accompanied by hypersensitivity reaction (rash, fever, arthralgia, myalgia, lymphadenopathy, hepatitis, renal impairment, eosinophilia, granulocytopenia); suspend if severe abnormalities in liver function tests but no hypersensitivity reaction&#8212;discontinue permanently if significant liver function abnormalities recur; monitor patient closely if mild to moderate abnormalities in liver function tests with no hypersensitivity reaction.</p>\n</sectiondiv>\r\n<sectiondiv>\r\n<p outputclass=\"title\">Rash</p>\r\n<p>Rash, usually in first 6 weeks, is most common side-effect; incidence reduced if introduced at low dose and dose increased gradually (after 14 days); Discontinue permanently if severe rash or if rash accompanied by blistering, oral lesions, conjunctivitis, facial oedema, general malaise or hypersensitivity reactions; if rash mild or moderate may continue without interruption but dose should not be increased until rash resolves.</p>\n</sectiondiv>\r\n<sectiondiv>\r\n<p outputclass=\"title\">Osteonecrosis</p>\r\n<p>For more information see <xref format=\"dita\" href=\"#PHP78275\" type=\"bookmark\" namespace=\"/treatment-summaries/hiv-infection\">HIV infection</xref>.</p>\n</sectiondiv>\n</section>\r\n\r\n</body>\n</topic>\n<topic id=\"PHP54620\" outputclass=\"hepaticImpairment\" parent=\"/drugs/nevirapine\">\n<title>Hepatic impairment</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Manufacturer advises avoid modified-release preparation&#8212;no information available; use &#8216;immediate-release&#8217; preparation with caution in moderate impairment and avoid in severe impairment.</p>\n<p>Use with caution in patients with chronic hepatitis B or C (at greater risk of hepatic side effects).</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP68257\" outputclass=\"renalImpairment\" parent=\"/drugs/nevirapine\">\n<title>Renal impairment</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Manufacturer advises avoid modified-release preparation&#8212;no information available.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP68193\" outputclass=\"monitoringRequirements\" parent=\"/drugs/nevirapine\">\n<title>Monitoring requirements</title>\n<body>\n<section outputclass=\"monitoringOfPatientParameters\">\n<sectiondiv>\n<p outputclass=\"title\">Hepatic disease</p>\n<p>Close monitoring of liver function required during first 18 weeks; monitor liver function before treatment then every 2 weeks for 2 months then after 1 month and then regularly.</p>\n</sectiondiv>\n<sectiondiv>\n<p outputclass=\"title\">Rash</p>\n<p>Monitor closely for skin reactions during first 18 weeks.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP54461\" outputclass=\"patientAndCarerAdvice\" rev=\"1.15\" parent=\"/drugs/nevirapine\">\n<title>Patient and carer advice</title>\n<body>\n<section outputclass=\"adviceAroundMissedDoses\">\n<title>Missed doses</title>\n<sectiondiv>\n<p>If a dose is more than 8 hours late with the &#8216;immediate-release&#8217; preparation (or more than 12 hours late with the modified-release preparation), the missed dose should not be taken and the next dose should be taken at the usual time.</p>\n</sectiondiv>\n</section>\n<section outputclass=\"generalPatientAdvice\">\n<sectiondiv>\n<p outputclass=\"title\">Hypersensitivity reactions</p>\n<p>Patients or carers should be told how to recognise hypersensitivity reactions and advised to discontinue treatment and seek immediate medical attention if severe skin reaction, hypersensitivity reactions, or symptoms of hepatitis develop.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP3827-medicinalForms\" outputclass=\"medicinalForms\" parent=\"/drugs/nevirapine\">\n<title>Medicinal forms</title>\n<body>\n<section outputclass=\"licensingVariationStatement\">\n<p>There can be variation in the licensing of different medicines containing the same drug.</p>\n</section>\n</body>\n</topic>\n<parents>\n<xref format=\"dita\" scope=\"local\" type=\"drugs\" href=\"#drugs\" title=\"Drugs\" namespace=\"/drugs\">Drugs</xref>\n</parents>\n<children>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP76878\" title=\"Tablet\" namespace=\"/drugs/nevirapine/tablet\">Tablet</xref>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP76892\" title=\"Modified-release tablet\" namespace=\"/drugs/nevirapine/modified-release-tablet\">Modified-release tablet</xref>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP76885\" title=\"Oral suspension\" namespace=\"/drugs/nevirapine/oral-suspension\">Oral suspension</xref>\n</children>\n<backlinks>\n<xref format=\"dita\" scope=\"local\" type=\"drugClassifications\" href=\"#PHP106980\" namespace=\"/drug-classifications\" title=\"Drug classifications\" count=\"1\" rel=\"backlink\">Drug classifications</xref>\n<xref format=\"dita\" scope=\"local\" type=\"treatmentSummary\" href=\"#PHP78143\" namespace=\"/treatment-summaries/contraceptives-interactions\" title=\"Contraceptives, interactions\" count=\"1\" rel=\"backlink\">Contraceptives, interactions</xref>\n<xref format=\"dita\" scope=\"local\" type=\"treatmentSummary\" href=\"#PHP78558\" namespace=\"/treatment-summaries/emergency-treatment-of-poisoning\" title=\"Emergency treatment of poisoning\" count=\"1\" rel=\"backlink\">Emergency treatment of poisoning</xref>\n</backlinks>\n<links>\n<xref format=\"dita\" scope=\"local\" type=\"interaction\" href=\"#bnf_int_843\" namespace=\"/interactions/list-of-drug-interactions/antivirals/nevirapine\" title=\"Nevirapine\" count=\"1\" rel=\"link\">Nevirapine</xref>\n<xref format=\"dita\" scope=\"local\" type=\"treatmentSummary\" href=\"#PHP78608\" namespace=\"/treatment-summaries/acute-porphyrias\" title=\"Acute porphyrias\" count=\"1\" rel=\"link\">Acute porphyrias</xref>\n<xref format=\"dita\" scope=\"local\" type=\"treatmentSummary\" href=\"#PHP78275\" namespace=\"/treatment-summaries/hiv-infection\" title=\"HIV infection\" count=\"1\" rel=\"link\">HIV infection</xref>\n<xref format=\"dita\" scope=\"local\" type=\"#drugs\" href=\"#drugs\" namespace=\"/drugs\" title=\"Drugs\" count=\"1\" rel=\"link\">Drugs</xref>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP76878\" namespace=\"/drugs/nevirapine/tablet\" title=\"Tablet\" count=\"1\" rel=\"link\">Tablet</xref>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP76892\" namespace=\"/drugs/nevirapine/modified-release-tablet\" title=\"Modified-release tablet\" count=\"1\" rel=\"link\">Modified-release tablet</xref>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP76885\" namespace=\"/drugs/nevirapine/oral-suspension\" title=\"Oral suspension\" count=\"1\" rel=\"link\">Oral suspension</xref>\n</links>\n</topic>",
    "id": "PHP3827",
    "outputclass": "drug",
    "rev": "1.11",
    "type": "drug",
    "namespace": "/drugs/nevirapine",
    "basename": "nevirapine",
    "title": "NEVIRAPINE",
    "interactants": [
        {
            "id": "bnf_int_843",
            "label": "Nevirapine"
        }
    ],
    "vtmid": "108704001",
    "drugClassification": [
        "Non-nucleoside reverse transcriptase inhibitors"
    ],
    "primaryDomainOfEffect": {
        "": {
            "domain": "",
            "therapeuticUses": {}
        }
    },
    "indicationsAndDoses": {
        "indicationAndDoseGroups": [
            {
                "indications": [
                    {
                        "textContent": "HIV infection in combination with other antiretroviral drugs (initial dose)",
                        "html": "HIV infection in combination with other antiretroviral drugs (initial dose)"
                    }
                ],
                "specificity": {
                    "routes": [
                        "mouth using immediate-release medicines"
                    ],
                    "textContent": "By mouth using immediate-release medicines",
                    "html": "By mouth using immediate-release medicines"
                },
                "adult": [
                    {
                        "textContent": "Initially 200 mg once daily for first 14 days, initial dose titration using &#8216;immediate-release&#8217; preparation should not exceed 28 days; if rash occurs and is not resolved within 28 days, alternative treatment should be sought. If treatment interrupted for more than 7 days, restart using the lower dose of the &#8216;immediate-release&#8217; preparation for the first 14 days as for new treatment.",
                        "html": "<p>Initially 200&#8239;mg once daily for first 14 days, initial dose titration using &#8216;immediate-release&#8217; preparation should not exceed 28 days; if rash occurs and is not resolved within 28 days, alternative treatment should be sought. If treatment interrupted for more than 7 days, restart using the lower dose of the &#8216;immediate-release&#8217; preparation for the first 14 days as for new treatment.</p>"
                    }
                ]
            },
            {
                "indications": [
                    {
                        "textContent": "HIV infection in combination with other antiretroviral drugs (maintenance dose following initial dose titration if no rash present)",
                        "html": "HIV infection in combination with other antiretroviral drugs (maintenance dose following initial dose titration if no rash present)"
                    }
                ],
                "specificity": {
                    "routes": [
                        "mouth using modified-release medicines"
                    ],
                    "textContent": "By mouth using modified-release medicines",
                    "html": "By mouth using modified-release medicines"
                },
                "adult": [
                    {
                        "textContent": "200 mg twice daily.",
                        "html": "<p>200&#8239;mg twice daily.</p>"
                    },
                    {
                        "textContent": "400 mg once daily.",
                        "html": "<p>400&#8239;mg once daily.</p>"
                    }
                ]
            }
        ]
    },
    "contraindications": {
        "contraindications": [
            {
                "type": "contraindications",
                "textContent": "Acute porphyrias",
                "html": "<xref format=\"dita\" href=\"#PHP78608\" type=\"bookmark\" namespace=\"/treatment-summaries/acute-porphyrias\">Acute porphyrias</xref>",
                "references": [
                    {
                        "id": "PHP78608",
                        "label": "Acute porphyrias"
                    }
                ]
            },
            {
                "type": "contraindications",
                "textContent": "post-exposure prophylaxis",
                "html": "post-exposure prophylaxis"
            }
        ]
    },
    "cautions": {
        "cautions": [
            {
                "type": "cautions",
                "textContent": "Females (at greater risk of hepatic side effects)",
                "html": "Females (at greater risk of hepatic side effects)"
            },
            {
                "type": "cautions",
                "textContent": "high CD4 cell count (at greater risk of hepatic side effects)",
                "html": "high CD4 cell count (at greater risk of hepatic side effects)"
            }
        ],
        "importantAdvice": [
            {
                "type": "importantAdvice",
                "title": "Hepatic effects",
                "textContent": "Patients with chronic hepatitis B or C, high CD4 cell count, and women are at increased risk of hepatic side effects&#8212;if plasma HIV-1 RNA detectable, manufacturer advises avoid in women with CD4 cell count greater than 250 cells/mm3 or in men with CD4 cell count greater than 400 cells/mm3 unless potential benefit outweighs risk.",
                "html": "<p>Patients with chronic hepatitis B or C, high CD4 cell count, and women are at increased risk of hepatic side effects&#8212;if plasma HIV-1 RNA detectable, manufacturer advises avoid in women with CD4 cell count greater than 250&#8239;cells/mm<sup>3</sup> or in men with CD4 cell count greater than 400&#8239;cells/mm<sup>3</sup> unless potential benefit outweighs risk.</p>"
            }
        ]
    },
    "interactions": {
        "general": [
            {
                "type": "general",
                "textContent": "Appendix 1 (nevirapine).",
                "html": "<p>Appendix 1 (nevirapine).</p>"
            }
        ]
    },
    "sideEffects": {
        "general": {
            "frequencies": {
                "commonOrVeryCommon": [
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "Abdominal pain",
                        "html": "Abdominal pain",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "diarrhoea",
                        "html": "diarrhoea",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "fatigue",
                        "html": "fatigue",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "fever",
                        "html": "fever",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "granulocytopenia",
                        "html": "granulocytopenia",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "headache",
                        "html": "headache",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "hepatitis",
                        "html": "hepatitis",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "hypersensitivity reactions (may involve hepatic reactions and rash)",
                        "html": "hypersensitivity reactions (may involve hepatic reactions and rash)",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "nausea",
                        "html": "nausea",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "rash",
                        "html": "rash",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "Stevens-Johnson syndrome",
                        "html": "Stevens-Johnson syndrome",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "toxic epidermal necrolysis",
                        "html": "toxic epidermal necrolysis",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "vomiting",
                        "html": "vomiting",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    }
                ],
                "uncommon": [
                    {
                        "type": "uncommon",
                        "textContent": "Anaemia",
                        "html": "Anaemia",
                        "frequency": "uncommon",
                        "specificity": {
                            "textContent": "Uncommon",
                            "html": "Uncommon"
                        }
                    },
                    {
                        "type": "uncommon",
                        "textContent": "arthralgia",
                        "html": "arthralgia",
                        "frequency": "uncommon",
                        "specificity": {
                            "textContent": "Uncommon",
                            "html": "Uncommon"
                        }
                    },
                    {
                        "type": "uncommon",
                        "textContent": "myalgia",
                        "html": "myalgia",
                        "frequency": "uncommon",
                        "specificity": {
                            "textContent": "Uncommon",
                            "html": "Uncommon"
                        }
                    }
                ],
                "notKnown": [
                    {
                        "type": "notKnown",
                        "textContent": "Osteonecrosis",
                        "html": "Osteonecrosis",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    }
                ]
            }
        },
        "advice": [
            {
                "type": "advice",
                "title": "Hepatic effects",
                "textContent": "Potentially life-threatening hepatotoxicity including fatal fulminant hepatitis reported usually in first 6 weeks; discontinue permanently if abnormalities in liver function tests accompanied by hypersensitivity reaction (rash, fever, arthralgia, myalgia, lymphadenopathy, hepatitis, renal impairment, eosinophilia, granulocytopenia); suspend if severe abnormalities in liver function tests but no hypersensitivity reaction&#8212;discontinue permanently if significant liver function abnormalities recur; monitor patient closely if mild to moderate abnormalities in liver function tests with no hypersensitivity reaction.",
                "html": "<p>Potentially life-threatening hepatotoxicity including fatal fulminant hepatitis reported usually in first 6 weeks; discontinue permanently if abnormalities in liver function tests accompanied by hypersensitivity reaction (rash, fever, arthralgia, myalgia, lymphadenopathy, hepatitis, renal impairment, eosinophilia, granulocytopenia); suspend if severe abnormalities in liver function tests but no hypersensitivity reaction&#8212;discontinue permanently if significant liver function abnormalities recur; monitor patient closely if mild to moderate abnormalities in liver function tests with no hypersensitivity reaction.</p>"
            },
            {
                "type": "advice",
                "title": "Rash",
                "textContent": "Rash, usually in first 6 weeks, is most common side-effect; incidence reduced if introduced at low dose and dose increased gradually (after 14 days); Discontinue permanently if severe rash or if rash accompanied by blistering, oral lesions, conjunctivitis, facial oedema, general malaise or hypersensitivity reactions; if rash mild or moderate may continue without interruption but dose should not be increased until rash resolves.",
                "html": "<p>Rash, usually in first 6 weeks, is most common side-effect; incidence reduced if introduced at low dose and dose increased gradually (after 14 days); Discontinue permanently if severe rash or if rash accompanied by blistering, oral lesions, conjunctivitis, facial oedema, general malaise or hypersensitivity reactions; if rash mild or moderate may continue without interruption but dose should not be increased until rash resolves.</p>"
            },
            {
                "type": "advice",
                "references": [
                    {
                        "id": "PHP78275",
                        "label": "HIV infection"
                    }
                ],
                "title": "Osteonecrosis",
                "textContent": "For more information see HIV infection.",
                "html": "<p>For more information see <xref format=\"dita\" href=\"#PHP78275\" type=\"bookmark\" namespace=\"/treatment-summaries/hiv-infection\">HIV infection</xref>.</p>"
            }
        ]
    },
    "hepaticImpairment": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Manufacturer advises avoid modified-release preparation&#8212;no information available; use &#8216;immediate-release&#8217; preparation with caution in moderate impairment and avoid in severe impairment.\n\nUse with caution in patients with chronic hepatitis B or C (at greater risk of hepatic side effects).",
                "html": "<p>Manufacturer advises avoid modified-release preparation&#8212;no information available; use &#8216;immediate-release&#8217; preparation with caution in moderate impairment and avoid in severe impairment.</p><p>Use with caution in patients with chronic hepatitis B or C (at greater risk of hepatic side effects).</p>"
            }
        ]
    },
    "renalImpairment": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Manufacturer advises avoid modified-release preparation&#8212;no information available.",
                "html": "<p>Manufacturer advises avoid modified-release preparation&#8212;no information available.</p>"
            }
        ]
    },
    "monitoringRequirements": {
        "patientParameters": [
            {
                "type": "patientParameters",
                "title": "Hepatic disease",
                "textContent": "Close monitoring of liver function required during first 18 weeks; monitor liver function before treatment then every 2 weeks for 2 months then after 1 month and then regularly.",
                "html": "<p>Close monitoring of liver function required during first 18 weeks; monitor liver function before treatment then every 2 weeks for 2 months then after 1 month and then regularly.</p>"
            },
            {
                "type": "patientParameters",
                "title": "Rash",
                "textContent": "Monitor closely for skin reactions during first 18 weeks.",
                "html": "<p>Monitor closely for skin reactions during first 18 weeks.</p>"
            }
        ]
    },
    "patientAndCarerAdvice": {
        "adviceAroundMissedDoses": [
            {
                "type": "adviceAroundMissedDoses",
                "textContent": "If a dose is more than 8 hours late with the &#8216;immediate-release&#8217; preparation (or more than 12 hours late with the modified-release preparation), the missed dose should not be taken and the next dose should be taken at the usual time.",
                "html": "<p>If a dose is more than 8 hours late with the &#8216;immediate-release&#8217; preparation (or more than 12 hours late with the modified-release preparation), the missed dose should not be taken and the next dose should be taken at the usual time.</p>"
            }
        ],
        "generalPatientAdvice": [
            {
                "type": "generalPatientAdvice",
                "title": "Hypersensitivity reactions",
                "textContent": "Patients or carers should be told how to recognise hypersensitivity reactions and advised to discontinue treatment and seek immediate medical attention if severe skin reaction, hypersensitivity reactions, or symptoms of hepatitis develop.",
                "html": "<p>Patients or carers should be told how to recognise hypersensitivity reactions and advised to discontinue treatment and seek immediate medical attention if severe skin reaction, hypersensitivity reactions, or symptoms of hepatitis develop.</p>"
            }
        ]
    },
    "medicinalForms": {
        "licensingVariationStatement": [
            {
                "type": "licensingVariationStatement",
                "textContent": "There can be variation in the licensing of different medicines containing the same drug.",
                "html": "<p>There can be variation in the licensing of different medicines containing the same drug.</p>"
            }
        ]
    },
    "children": {
        "medicinalForm": [
            {
                "id": "PHP76878",
                "label": "Tablet",
                "type": "medicinalForm"
            },
            {
                "id": "PHP76892",
                "label": "Modified-release tablet",
                "type": "medicinalForm"
            },
            {
                "id": "PHP76885",
                "label": "Oral suspension",
                "type": "medicinalForm"
            }
        ]
    },
    "backlinks": {
        "drugClassifications": [
            {
                "id": "PHP106980",
                "label": "Drug classifications",
                "type": "drugClassifications"
            }
        ],
        "treatmentSummary": [
            {
                "id": "PHP78143",
                "label": "Contraceptives, interactions",
                "type": "treatmentSummary"
            },
            {
                "id": "PHP78558",
                "label": "Emergency treatment of poisoning",
                "type": "treatmentSummary"
            }
        ]
    },
    "links": {
        "interaction": [
            {
                "id": "bnf_int_843",
                "label": "Nevirapine",
                "type": "interaction"
            }
        ],
        "treatmentSummary": [
            {
                "id": "PHP78608",
                "label": "Acute porphyrias",
                "type": "treatmentSummary"
            },
            {
                "id": "PHP78275",
                "label": "HIV infection",
                "type": "treatmentSummary"
            }
        ],
        "#drugs": [
            {
                "id": "drugs",
                "label": "Drugs",
                "type": "#drugs"
            }
        ],
        "medicinalForm": [
            {
                "id": "PHP76878",
                "label": "Tablet",
                "type": "medicinalForm"
            },
            {
                "id": "PHP76892",
                "label": "Modified-release tablet",
                "type": "medicinalForm"
            },
            {
                "id": "PHP76885",
                "label": "Oral suspension",
                "type": "medicinalForm"
            }
        ]
    }
}